US Residual DNA Testing Market Size, Share, Trends, and Growth Forecast 2035
According to Payal Rabde, who specializes in detecting and quantifying residual host cell DNA, quality control and release testing, advanced molecular techniques, FDA, EMA, WHO, and ICH, and improving product quality and patient safety, with 4+ years of experience in market research and industry analysis, extensive research indicates strong growth opportunities in the U.S. residual DNA testing market. The global U.S. residual DNA testing market size was estimated at USD 154.39 million in 2025 and is predicted to increase from USD 163.93 million in 2026 to approximately USD 281.22 million by 2035, expanding at a CAGR of 6.18% from 2026 to 2035. Her analysis highlights the increasing adoption of cell and gene therapies, digital PCR (dPCR) and qPCR technologies, automated quality control workflows, high-throughput analytical platforms, and advanced molecular testing solutions. The research also examines the competitive strategies of key industry participants, including, Catalent Cell & Gene Therapy, Lonza Houston, Charles River Laboratories, Resilience, and Oxford Biomedica Solutions, shaping the future by advanced molecular testing technologies, AI-driven and automated quality control systems, rapid growth in biologics vaccines, and cell and gene therapies, high-through analytical platforms, and next-generation analytical solutions in the global U.S. residual DNA testing market.
Last Updated : 23 July 2026
Category: Biotechnology
Insight Code: 5972
Format: PDF / PPT / Excel